Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGSC 20% Efficacy, Safety, and PK in Primary Immunodeficiency
NCT01412385Phase 3Completed
- Sponsor
- Takeda
- Start
- Jun 2011
- Primary completion
- May 2014
- Modality
- Biologic
- Countries
- 5
01
Overview
A Phase 3 trial of polyvalent human immunoglobulin in primary immunodeficiency disease (PID), sponsored by Takeda. Started Jun 2011; status: completed.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
primary immunodeficiency disease (PID)
Beyond the preview
Go deeper on NCT01412385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01412385.